A Phase 3 trial of the antibiotic Lefamulin reported that the drug achieved its primary endpoint in treating community acquired bacterial pneumonia (CABP).

In lefamulin’s phase 3 trial, LEAP 1, the antibiotic met primary endpoint of non-inferiority compared to moxifloxacin with or without adjunctive linezolid for early clinical response (ECR) — as assessed 3 to 5 days following initiation of therapy. Lefamulin returned a 87.3% ECR rate, versus moxifloxacin’s 90.2% with or without linezolid.

The treatment, which in trials was combined with IV in CABP patients, represents the first new class of positive-results trial antibiotics for pneumonia, according to Nabriva Therapeutics.